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Summary
Foxp3+ regulatory T (Treg) cells are essential to maintain immune
homeostasis, yet controversy exists about the stability of this cell popula-
tion. Bcl6-deficient (Bcl6/) mice develop severe and spontaneous T
helper type 2 (Th2) inflammation and Bcl6-deficient Treg cells are ineffec-
tive at controlling Th2 responses. We used a lineage tracing approach to
analyse the fate of Treg cells in these mice. In the periphery of Bcl6/
mice, increased numbers of Foxp3-negative ‘exTreg’ cells were found, par-
ticularly in the CD25+ population. ExTreg cells from Bcl6/ mice
expressed increased interleukin-17 (IL-17) and extremely elevated levels of
Th2 cytokines compared with wild-type exTreg cells. Although Treg cells
normally express only low levels of cytokines, Treg cells from Bcl6/
mice secreted higher levels of IL-4, IL-5, IL-13 and IL-17 than wild-type
conventional T cells. Next, Treg-specific conditional Bcl6-deficient
(Bcl6Foxp3/) mice were analysed. Bcl6Foxp3/ mice do not develop
inflammatory disease, indicating a requirement for non-Treg cells for
inflammation in Bcl6/ mice, and have normal numbers of exTreg cells.
We induced Th2-type allergic airway inflammation in Bcl6Foxp3/ mice,
and found that while exTreg cytokine expression was normal, Bcl6-defi-
cient Treg cells expressed higher levels of the Th2-specific regulator Gata3
than Bcl6+ Treg cells. Bcl6Foxp3/ mice had increased numbers of Th2
cells after induction of airway inflammation and increased T cells in the
bronchoalveolar lavage fluid. These data show both Treg-intrinsic and
Treg-extrinsic roles for Bcl6 in controlling Treg cell stability and Th2
inflammation, and support the idea that Bcl6 expression in Treg cells is
critical for controlling Th2 responses.
Keywords: Bcl6; ex-regulatory T cells; FoxP3; regulatory T cells; T helper
type 2 differentiation.
Introduction
Foxp3+ regulatory T (Treg) cells are essential for immu-
nological tolerance and are required for curtailing inflam-
matory responses in a number of autoimmune diseases.1
Despite the central role of Treg cells in maintaining self-
tolerance, there are unresolved questions about the stabil-
ity and plasticity of the Treg phenotype in vivo. Most
Treg cells maintain high Foxp3 levels following adoptive
transfer in a non-pathogenic setting.2,3 Foxp3+ Treg cells
can differentiate into cytokine-secreting Foxp3 T
cells when cultured with cytokines in vitro.4–6 Further,
studies employing Foxp3 reporter mice reveal that Foxp3
expression is unstable in inflammatory settings and Treg
cells that lose Foxp3 expression, termed ‘exTreg’ cells, can
acquire the cytokine production capabilities of effector T
cells.7 Recently, in a mouse model of arthritis, interleu-
kin-6 (IL-6) was shown to promote the conversion of
Treg cells into T helper type 17 (Th17) -like pathogenic
exTreg cells.8
Another example of apparent Treg cell plasticity is the
finding that CD4+ CD25 Foxp3+ Treg cells can convert
to Bcl6-expressing follicular helper T cells in mouse Pe-
yer’s patches.9 Intriguingly, transforming growth factor-b
and retinoic acid present in the gut can induce miR-10a,
a microRNA that targets Bcl6, so maintaining Treg cell
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stability and preventing Treg cell conversion to follicular
helper T cells.10 These studies showing Treg plasticity
contrast with studies showing that Foxp3+ Treg cells are
extremely stable in vivo, under a variety of conditions.11–13
A recent publication reported that exTreg cells are not
derived from stable thymus-derived Treg cells, but rather
from a conventional CD4 T-cell population that tran-
siently up-regulates Foxp3 following activation in the
periphery.14 The extent to which these transient and
unstable Foxp3+ cells act as Treg cells in vivo remains
unclear. Further, the relationship of these transient
Foxp3-expressing T cells to Treg cells induced in the
periphery (peripheral Treg cells) is not known.12 Gener-
ally it is accepted that peripheral Treg cells are more
unstable than thymus-derived Treg cells.12 The available
data show that 90–95% of thymus-derived Foxp3+ T cells
are extremely stable, whereas Foxp3+ T cells formed in
the peripheral lymphoid organs contain a high fraction of
unstable Foxp3+ T cells.4,13,15 Further, unstable Treg cells
are particularly enriched in the CD25low Treg population,
while stable Treg cells are CD25high.8 CD25low Treg cells
may represent recently emerged peripheral Treg cells that
are not fully committed to the Treg lineage and are still
plastic16.
Bcl6-deficient mice develop a spontaneous and severe
Th2-type inflammatory disease including myocarditis and
pulmonary vasculitis,17–20 and Bcl6-deficient Treg cells fail
to control Th2 inflammation.21 Bcl6 is required to repress
Gata3 activity in Treg cells, and Bcl6-deficient Treg cells
display an intrinsic increase in Th2 gene and microRNA-
21 (miR-21) expression.21,22 Bcl6-deficient Treg cells from
mixed bone marrow chimeras displayed a weaker expres-
sion of Th2 genes than Treg cells from Bcl6-deficient
mice, indicating that a combination of wild-type Treg
cells and the lack of Th2 inflammation in these mice was
suppressing the up-regulation of Th2 cytokines by Bcl6-
deficient Treg cells.21 Although Bcl6-deficient Treg cells
had a strong Th2 gene expression bias, these cells did not
show any reduction or loss of the classical Treg gene sig-
nature. Further, Bcl6-deficient Treg cells exhibited normal
suppressive activity in vitro and in an in vivo colitis
model.21 Hence, Bcl6-deficient Treg cells are largely nor-
mal, but the presence of Th2 inflammation induces
abnormally strong Th2 gene expression. One explanation
for the failure of Bcl6-deficient Treg cells to control Th2
inflammation is that the strong inflammatory environ-
ment in Bcl6-deficient mice promotes Th2 cytokine
expression by Treg cells, short-circuiting the suppression
of Th2 responses. Another possibility is that Bcl6 is
required to stabilize Treg cells in the presence of Th2
inflammation, and Bcl6-deficient Treg cells exposed to
Th2 inflammation undergo loss of Foxp3 expression and
reprogramming of the cells to a Th2 effector fate.
To test this hypothesis, we developed a system whereby
we could track exTreg cells in Bcl6-deficient mice. We
find that in a Th2-type inflammatory environment, Bcl6-
deficient Treg cells lose Foxp3 expression at a higher rate
than wild-type Treg cells; however, in a non-inflamma-
tory environment, Bcl6-deficient Treg cells are as stable as
wild-type Treg cells. We further analyse the intrinsic role
for Bcl6 in Treg cells for controlling Treg stability by test-
ing Treg-specific Bcl6-deficient mice in an induced model
of Th2 inflammation. Our data show that Bcl6 maintains
Treg stability by both Treg-extrinsic and Treg-intrinsic
pathways, and further define the role for Bcl6 in Treg
cells for controlling Th2 responses.
Materials and methods
Mice
Bcl6/ and Bcl6+/ mice on a mixed C57BL/6-129Sv
background have been previously described.17,18 Foxp3-
GFP-Cre and Rosa-YFP mice were obtained from Jackson
Laboratories (Bar Harbor, ME). Bcl6+/ mice were mated
consecutively to these two strains to produce the FCRY
(Foxp3-gfp-Cre 9 Rosa-Yfp) strain. Mice were genotyped
for iCre and the Rosa-YFP alleles according to PCR pro-
tocols from Jackson Laboratories. Bcl6/ mice were used
between 3 and 6 weeks of age; wherever possible, Bcl6+/+
mice were littermate controls. Bcl6/ mice were used at
a young age because of their consistent early death on
this strain background. Conditional Bcl6fl/fl mice were
recently described.23 Rosa-RFP (td-Tomato) mice were
obtained from Jackson Laboratories and mated to Bcl6fl/fl
mice already mated to Foxp3-GFP-Cre mice. Genotyping
for the floxed Bcl6 allele was performed as described,23
and genotyping for iCre and Rosa-RFP was performed
according to PCR protocols from Jackson Laboratories.
Mice were bred under specific pathogen-free conditions
at the laboratory animal facility at the Indiana University
School of Medicine and were handled according to proto-
cols approved by the Indiana University School of Medi-
cine Animal Use and Care Committee.
Antibodies, flow cytometry and cell sorting
Flow cytometry analysis of Treg surface markers was per-
formed using anti-CD4 antibody (RM4-5; BD Bioscienc-
es, San Jose, CA) and anti-CD25 antibody (PC61.5;
eBioscience, San Diego, CA). Both Treg and exTreg cells
were primarily tracked by GFP and YFP/RFP expression.
Flow analysis was carried out on an LSR machine (Becton
Dickinson, Franklin Lakes, NJ) and data were analysed
using FLOWJO software (Tree Star, Inc., Ashland, OR).
For isolation of stable Treg and exTreg cells,
CD4+ CD25+ T cells were purified from Bcl6+/+ and
Bcl6/ FCRY mice using magnetic beads (Miltenyi Bio-
tech, San Diego, CA), followed by Fluorescence Activated
Cell Sorting (FACS) for pure GFP+ YFP+ (or
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GFP+ RFP+) stable Treg cells and GFP YFP+ (or
GFP RFP+) exTreg cells using a FACSAria cell sorter
(Becton Dickinson). Conventional T (Tconv) cells were
CD4+ CD25 T cells obtained during magnetic selection
of CD4+ CD25+ T cells. T cells were stimulated for 16 hr
with anti-CD3 and anti-CD28 antibodies (BD Bioscienc-
es), as described previously,21 before mRNA isolation.
Intracellular staining of Foxp3 and Gata3 protein was
performed on spleen cells stimulated with PMA plus
ionomycin as described elsewhere.21.
Gene expression analysis
Total cellular RNA was prepared using the Trizol method
(Life Technologies, Grand Island, NY), and cDNA was
prepared with the Transcriptor First Strand cDNA synthe-
sis kit (Roche, Indianapolis, IN). Quantitative PCR were
run by assaying each cDNA sample in triplicates with
Taqman assays (ABI) for each specific gene. Primer
sequences for Taqman assays are proprietary. Levels of
mRNA expression were normalized to b-tubulin (Tubb5)
mRNA levels, and differences between samples were anal-
ysed using the DDCt method. Gene expression levels of
reference samples were averaged at the DCt level of analy-
sis, and then individual levels of expression for each sam-
ple were calculated and these levels were averaged to
show in the graphs. Hence, the average normalized refer-
ence point can vary from a perfect 10, depending on the
variation within the set of reference control samples from
the average DCt.
Cytokine analysis
T cells were stimulated for 16 hr with anti-CD3 and anti-
CD28 antibodies (BD Biosciences), and then supernatants
were collected, as described.21 Cytokine levels in the
media supernatants were determined by multiplex ELISA
using the Milliplex MAP Kit (Millipore, Billerica, MA) as
described.24 Intracellular cytokine staining was performed
as described,21,23 on total spleen cells stimulated with
PMA plus ionomycin.
Airway inflammation model
Bcl6+ Foxp3-Cre+ ROSA-RFP (control) mice and BCL6fl/fl
Foxp3-Cre+ ROSA-RFP (Bcl6Foxp3/) mice were sensi-
tized intraperitoneally with ovalbumin (OVA) (Sigma, St
Louis, MO) adsorbed to alum (Sigma) at a dose of 20 lg
OVA/2 mg alum on days 0 and 7 of the protocol.24 Start-
ing on day 14, mice were challenged intranasally with
OVA for 5 consecutive days (100 lg/day). Mice were
killed by intraperitoneal injection of pentobarbital (5 mg/
mouse) 48 hr after the final intranasal challenge on day
18. The trachea was cannulated and lungs were lavaged
three times with 1 ml PBS to collect the bronchoalveolar
lavage (BAL). Cells recovered in BAL fluid were counted
with a haemocytometer. Eosinophils, neutrophils, T cells,
B cells and mononuclear cells in the BAL fluid were dis-
tinguished by cell size and by expression of CD3, B220,
CCR3, CD11c and MHC class II, and percentages of each
cell type were assessed by flow cytometry as described
previously.24 Paraffin-embedded lung sections were
stained with haematoxylin & eosin for evaluation of the
infiltration of inflammatory cells by light microscopy.
Inflammation was scored on a scale of 0–5, where 0 = no
inflammation of lung airways, 1 = faint inflammatory
infiltrate around airways, 2 = light inflammatory infiltrate
around airways, 3 = medium inflammatory infiltrate
around airways, 4 = heavy inflammatory infiltrate around
airways with inflammatory cells spreading into some por-
tions of lung parenchyma, 5 = heavy inflammatory infil-
trate around airways with inflammation spreading into
most of the lung parenchyma.
Statistical analysis
P-values were calculated using Student’s t-test or analysis
of variance. All calculations were made using GRAPHPAD
PRISM software (La Jolla, CA). A P-value < 005 was con-
sidered to show a significant difference.
Results
Stability of Treg cells in the absence of Bcl6
In order to perform lineage tracing of Bcl6/ Foxp3+
Treg cells in the context of Th2 inflammation, we crossed
Bcl6/ mice with Foxp3-GFP-Cre 9 Rosa26-YFP mice
(Fig. 1a). In these mice, the Foxp3-GFP-Cre+ Treg cells
excise the loxP-flanked stop codon in front of the YFP
gene, allowing for constitutive YFP expression from the
Rosa26 promoter. The Foxp3-Cre activity permanently
labels the Foxp3+ T cells and their progeny.7 This dual
reporter mouse strain enables tracing of Foxp3 induction
and down-regulation concurrently by two-colour flow
analysis of GFP and YFP expression (Fig. 1b, c). Because
of a delay between Foxp3 transcription (GFP expression)
and excision of the loxP-flanked stop cassette in the
Rosa26-YFP transgene by Cre, the GFP+ YFPloneg popu-
lation represents cells that recently up-regulated Foxp3
expression. Hence, GFP+ YFP+ cells represent ‘stable’
mature Treg cells and GFP– YFP+ cells represent ‘exTreg’
cells. Using this system, we then monitored the percent-
ages of stable Treg cells and exTreg cells in the thymus
and peripheral lymphoid organs in Foxp3-GFP-Cre
Rosa26-YFP Bcl6/ [FCRY knockout (KO)] mice rela-
tive to control Foxp3-GFP-Cre Rosa26-YFP Bcl6+/+
[FCRY wild-type (WT)] mice. Similarly to Bcl6/
mice,17–20 FCRY KO mice developed eosinophilic myo-
carditis and lung vasculitis at a high rate and died at an
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early age (data not shown). Hence, these mice develop
severe Th2 inflammation typical of the Bcl6/ mouse
phenotype. Analysis of the thymus in the FCRY WT and
FCRY KO mice demonstrated comparable percentages of
stable Treg and exTreg cells, thereby suggesting that the
Bcl6/ Treg cells are not intrinsically biased towards los-
ing Foxp3 expression or do not lose Foxp3 shortly after
their development (Fig. 2). We next looked in the periph-
eral Treg compartment. Our previous data showed that
the percentage of total Foxp3+ Treg cells was not signifi-
cantly altered in Bcl6/ mice;21 however, analysis of sta-
ble Treg and exTreg populations in the peripheral
lymphoid organs (spleen and lymph nodes) demonstrated
a significant increase in the percentage of exTreg cells in
the FCRY KO mice relative to FCRY WT mice (Fig. 3a,
b). Although Treg cells are largely CD25+, previous work
has shown that exTreg cells are found at a higher fre-
quency in the CD4+ CD25 cell population than in the
CD4+ CD25+ cell population.8 Indeed, for FCRY WT
mice, the average percentage of exTreg cells was increased
with the total CD4+ gate compared with the
CD4+ CD25+ gate (Fig. 3a, b). However, this pattern was
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Figure 1. A genetic system for tracking regula-
tory T (Treg) cell stability. (a) Mouse gene
constructs used in generation of Foxp3-GFP-
Cre-Rosa-YFP (FCRY) mice. (b) expected fluo-
rescence patterns for conventional T (Tconv)
cells, transient Treg, stable Treg and exTreg
cells. (c) Sample flow plot for GFP by YFP in
spleen cells from a FCRY mouse.
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Figure 2. Regulatory T (Treg) cell stability in the thymus of Bcl6/ mice. Data from the thymuses of Bcl6+/+ (wild-type; WT) and Bcl6/
(knockout; KO) Foxp3-GFP-Cre-Rosa-YFP (FCRY) mice, with representative flow plots on left and graphed data on right. Thymocytes were
gated for surface Treg markers (CD4+ CD25+) before GFP versus YFP analysis. The % of exTreg cells is calculated by the % GFP YFP+ cells
within the total YFP+ population. The numbers in large bold font in upper left and upper right quadrants are % of exTreg cells and % stable
Treg cells within the YFP+ population, and these percentages add up to 100%. The smaller numbers in italic font are the % of cells for each of
the four quadrants and all four of these numbers add up to 100%. Graphs show average exTreg cells  SE, with n = 8 to n = 12 mice of each
genotype. Data from four separate experiments were combined into each graph. Each symbol represents one mouse. Student’s t-tests were used
to calculate statistical significance and P-values. NS, not significant (P > 005).
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not observed with FCRY KO mice, as comparable per-
centages of exTreg cells were seen using either the total
CD4+ or the CD4+ CD25+ gate (Fig. 3a, b). Strikingly,
within the CD4+ CD25+ cell subset, the percentage of
exTreg cells in FCRY KO spleen and lymph nodes was
two to three times greater than in FCRY WT mice. This
result indicates that the Th2 inflammatory environment
in Bcl6/ mice potently de-stabilizes Treg cells and
markedly promotes the loss of Foxp3 expression at the
CD25+ Treg stage.
Potent Th2 responses by conventional T cells, Treg
cells and exTreg cells in the absence of Bcl6
ExTreg (GFP YFP+) cells have been reported to exhibit
an activated-memory phenotype, with reduced expression
of Treg signature genes, high CD44 expression and
acquisition of effector cytokine-producing ability
[interferon-c (IFN-c) or IL-17A], depending on the
microenvironment.7 To assess the effect of the Th2
inflammatory environment on the Treg and exTreg phe-
notype in Bcl6/ mice, we sorted CD4+ CD25 Tconv
cells, GFP+ YFP+ stable Treg cells and GFP YFP+ exT-
reg cells from FCRY WT and FCRY KO mice, activated
them in vitro and assessed their gene expression and
cytokine secretion signature. Consistent with the well-
demonstrated role for Bcl6 in inhibiting Th2 differentia-
tion,21,25 we noted increased expression of Th2 genes
(Gata3, Il4, Il5, Il13) in FCRY KO Tconv cells, relative
to FCRY WT Tconv cells (Fig. 4). This increased tran-
scription of Th2 genes translated into increased secretion
of Th2 cytokines by FCRY KO Tconv cells as shown in
Fig. 5. Although Il17a message and IL-17A expression were
increased in FCRY KO Tconv cells, Ifng message and IFN-c
secretion were not significantly different. Secretion of IL-10
was augmented in the Bcl6/ Tconv cells (Fig. 5), consis-
tent with previous work showing repression of IL-10 by
Bcl6.23,25
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KOFigure 3. Regulatory T (Treg) cell stability in
the periphery of Bcl6/ mice. Data from the
spleen of Bcl6+/+ (wild-type; WT) and Bcl6/
(knockout; KO) Foxp3-GFP-Cre-Rosa-YFP
(FCRY) mice, with representative flow plots on
left and graphed data on right. Splenocytes
were gated for either CD4+ (a) or
CD4+ CD25+ (b) cells before GFP versus YFP
analysis. The % of exTreg cells is calculated by
the % GFP– YFP+ cells within the total YFP+
population. The numbers in large bold font in
upper left and upper right quadrants are %
exTreg cells and % stable Treg cells within the
YFP+ population, and these percentages add
up to 100%. The smaller numbers in italic font
are the % of cells for each of the four quad-
rants and all four of these numbers add up to
100%. Graphs show average exTreg cells  SE,
with n = 8 to n = 12 mice of each genotype.
Data from four separate experiments were
combined into each graph. Each symbol repre-
sents one mouse. Student’s t-tests were used to
calculate statistical significance and P-values.
NS, not significant (P > 005), *P < 005,
****P < 0001.
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In the stable Treg cell fraction, overall cytokine gene
expression was reduced in both Bcl6+/+ and Bcl6/
Treg cells compared with the respective Tconv cells,
consistent with a role of Foxp3 in limiting effector cyto-
kine expression in Treg cells. However, Treg cells from
the FCRY KO mice exhibited a strong Th2 gene expres-
sion bias (Fig. 4); specifically, Il4, Il5, Il13 and Gata3
mRNAs were strongly elevated in Bcl6/ Treg cells,
confirming that Bcl6 represses Th2 gene expression in
Treg cells.21 The increased Th2 gene expression in
Bcl6/ Treg cells corresponded with a very strong
increase in Th2 cytokine secretion, such that Bcl6/
Treg cells produced 300-fold higher levels of IL-4 and
IL-13 than Bcl6+/+ Treg cells (Fig. 5). Even more strik-
ingly, Bcl6/ Treg cells secreted more IL-4 (49 higher),
IL-5 (309 higher) and IL-13 (309 higher) than Bcl6+/+
Tconv cells (Fig. 5). These data are consistent with the
ability of Bcl6/ Treg cells to promote rather than sup-
press Th2-type inflammation in an allergic airway dis-
ease model.21 Interleukin-10 secretion was increased by
Bcl6/ Treg cells (Figs 5 and 6), consistent with earlier
data that Bcl6 represses Il10 mRNA in Treg cells as well
as in Tconv cells.21
In the exTreg cell fraction, there was a continued trend
of much greater Th2 gene and cytokine expression from
Bcl6/ cells (Figs 4 and 5). Secretion of IL-17 was also
increased from Bcl6/ exTreg cells but that of IFN-c was
not. Consistent with a loss of Foxp3 repression, Th2 cyto-
kine expression by Bcl6/ exTreg cells was much higher
than Th2 cytokine expression from Bcl6/ Treg cells and
was in the range of Th2 cytokine expression by Bcl6/
Tconv cells (Figs 4, 5 and 6). Bcl6+/+ exTreg cells showed
little to no increase in IFN-c, IL-5 and IL-17 secretion
compared with Bcl6+/+ Treg cells, but did show a notable
increase in IL-4, IL-5 and IL-13 secretion (Fig. 6). The
increase in Th2 cytokines by Bcl6/ exTreg cells com-
pared with Bcl6/ Treg cells, especially for IL-4, was
overall far greater than the corresponding increase of
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Figure 4. Cytokine gene expression in Bcl6/
regulatory T (Treg) and exTreg cells.
CD4+ CD25 conventional T (Tconv) cells
and CD4+ CD25+ cells from Bcl6+/+ (wild-
type; WT) and Bcl6/ (knockout; KO) FCRY
mice were obtained by magnetic bead selec-
tion. CD4+ CD25+ cells were further separated
into Treg cells (GFP+ YFP+) and exTreg cells
(GFP YFP+) by cell sorting. Isolated cells
were stimulated 16 hr with anti-CD3 and anti-
CD28 antibodies before harvest for RNA isola-
tion. Gene expression was assessed by quantita-
tive PCR. Data shown are representative of
two different experiments. Graphs show rela-
tive gene expression, and bars are average
fold  SE and wild-type Tconv cells set as 1.
n = 3 to n = 5 of each genotype. Numbers on
top of bars indicate fold-increase of KO to
WT. Student’s t-tests were used to calculate
statistical significance and P-values. NS, not
significant (P > 005), *P < 005, **P < 001,
***P < 0001.
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cytokines by Bcl6+/+ exTreg cells compared with Bcl6+/+
Treg cells (Fig. 6). Hence, these data show that Bcl6 is a
strong and specific repressor of Th2 gene expression, not
only in Tconv cells, but also in Treg and exTreg cells.
Treg-specific conditional knockout mice reveal
Treg-intrinsic and Treg-extrinsic roles for Bcl6
We next wished to address whether the increased loss of
Foxp3 expression and increased expression of cytokines
in Bcl6/ Treg and exTreg cells was due to inflammatory
disease in the mice, or due to an intrinsic effect of loss of
Bcl6 on Treg cell stability. We therefore used conditional
knockout mice for Bcl623 and Foxp3-GFP-Cre to condi-
tionally delete Bcl6 in the Treg lineage (Fig. 7a). These
Bcl6Foxp3/ mice were then mated to mice with a similar
conditional Rosa26 allele as shown in Fig. 1, except
expressing RFP instead of YFP. In these Foxp3-GFP-Cre
Rosa26-RFP (FCRR) mice, stable Treg cells are
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Figure 5. Cytokine secretion by Bcl6/ regu-
latory T (Treg) cells and exTreg cells.
CD4+ CD25 conventional T (Tconv) cells
and CD4+ CD25+ cells from Bcl6+/+ (wild-
type; WT) and Bcl6/ (knockout; KO) FCRY
mice were obtained by magnetic bead selec-
tion. CD4+ CD25+ cells were further separated
into Treg cells (GFP+ YFP+) and exTreg cells
(GFP– YFP+) by cell sorting. Isolated cells were
stimulated for 16 hr with anti-CD3 and anti-
CD28 antibodies, at which time cell superna-
tants were taken. Cytokine levels were deter-
mined by multiplex ELISA. Graphs show
relative cytokine secretion, and bars are average
fold  SE and wild-type Tconv cells set as 1.
n = 3 to n = 5 of each genotype. Numbers on
top of bars indicate fold-increase of KO to
WT. Student’s t-tests were used to calculate
statistical significance and P-values. NS, not
significant (P > 005), *P < 005, **P < 001,
***P < 0001.
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GFP+ RFP+ and exTreg cells are GFP RFP+. There was
no difference in the overall numbers of Treg cells in
Bcl6Foxp3/ mice compared with control mice (Fig. 7b
and data not shown). In contrast to Bcl6/ mice, there
was also no difference in the generation of exTreg cells
between Bcl6Foxp3/ and control FCRR mice in the
steady state (Fig. 7b, c). Also, unlike Bcl6/ mice,
Bcl6Foxp3/ mice do not develop inflammatory disease
or significant Th2 cell skewing (data not shown). Hence,
it is likely that Treg-extrinsic factors, such as the strong
Th2 inflammatory environment in Bcl6/ mice, promote
the increase in exTreg cells in Bcl6/ mice. To test
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Figure 7. Regulatory T (Treg) stability in Treg-specific conditional Bcl6/ mice. (a) Quantitative PCR analysis of Bcl6 transcript between Treg-
specific conditional Bcl6/ (Bcl6Foxp3/) (conditional knockout; cKO) mice and control Bcl6+/+ (Bcl6Foxp3+/+) (wild-type; WT) mice.
CD4+ CD25+ FoxP3+ (Treg) and CD4+ CD25 (conventional T; Tconv) cells were prepared by MACS separation and FACS isolation, then acti-
vated for 16 hr with anti-CD3 and anti-CD28 before RNA and cDNA preparation. Relative gene expression is shown, where Bcl6 expression is
normalized to tubb5. Data are average expression  SE from three WT and six cKO mice. The increase in Bcl6 mRNA expression in cKO Tconv
cells probably relates to an increase in Bcl6-expressing follicular helper T cells in these mice (unpublished data). (b) Data from the spleens of
Treg-specific conditional Bcl6/ (Bcl6Foxp3/) (cKO) mice and control Bcl6+/+ (Bcl6Foxp3+/+) (WT) mice, mated to a Foxp3-GFP-Cre-Rosa26-
RFP (FCRR) background. Representative flow plots of splenocytes gated for CD4+ expression before GFP versus RFP analysis. RFP was used
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to 100%. The % of exTreg cells is calculated by the % GFP RFP+ cells divided by the total RFP+ population. (c) ExTreg percentages in the
steady state (WT and cKO) or after induction of allergic airway inflammation [WT-AAD and cKO-AAD; allergic airway disease (AAD)]. Cells
shown are gated on total CD4+ T cells. (d) Percentages of exTreg cells after induction of allergic airway inflammation (WT-AAD and cKO-
AAD). Cells shown are gated on CD4+ CD25+ T cells. Graphs show average  SE, with n = 4 to n = 7 mice of each type. Data are shown is rep-
resentative of two different experiments. Each symbol represents one mouse. Analysis of variance was used to calculate statistical significance and
P-values. NS, not significant (P > 005), *P < 005, **P < 001
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whether Th2 inflammation could preferentially destabilize
Bcl6-deficient Treg cells, we induced Th2-type allergic
airway inflammation in control and Bcl6Foxp3/ FCRR
mice, where the antigen OVA in alum adjuvant is used
for systemic priming and subsequent airway challenge.24
However, while induction of Th2 inflammation in both
control and Bcl6Foxp3/ FCRR mice led to a significant
increase in exTreg cells compared with the steady state
(Fig. 7c), there was still no difference in exTreg genera-
tion between control and Bcl6-deficient Treg cells
(Fig. 7c). The data in Fig. 7(b) show exTreg cells gated
on total CD4+ T cells, and the percentage of exTreg cells
was not increased when a CD4+ CD25+ gate was used
(Fig. 7d). These data indicate that the Th2-type inflam-
matory environment in Bcl6/ mice destabilizes Treg
cells by a mechanism unique from the Th2-type inflam-
matory environment created in the OVA-Alum allergic
airway disease model.
We had previously shown that Bcl6-deficient Treg cells
from Bcl6/ mice were unable to suppress Th2 inflam-
mation and rather actually augmented Th2 inflamma-
tion.21 We therefore wondered if Bcl6-deficient Treg cells
affected the Th2 response in Bcl6Foxp3/ mice in the
OVA-Alum allergic airway disease model. T cells from
control and Bcl6Foxp3/ mice induced for allergic airway
disease were assessed for intracellular Gata3 and IL-4
expression as markers of Th2 responses. As shown in
Fig. 8(a), Tconv cells from Bcl6Foxp3/ mice, had signifi-
cantly increased numbers of Gata3+ and IL-4-expressing
cells than control mice, consistent with the idea that
Bcl6-deficient Treg cells are defective in controlling Th2
responses. The percentage of Tconv cells expressing IFN-c
was not different from control and Bcl6Foxp3/ mice,
indicating Th2 specificity to the defect in the Bcl6Foxp3/
mice. We next analysed Treg cells in control and
Bcl6Foxp3/ mice in the OVA-Alum allergic airway dis-
ease model. The overall number of Treg cells in
Bcl6Foxp3/ mice was significantly higher than in control
mice, indicating increased expansion of Bcl6-deficient
Treg cells in response to Th2 inflammation (Fig. 8b).
Even more striking, the fraction of Gata3+ cells within
the Bcl6-deficient Treg population was twofold higher
than in control mice (Fig. 8b). These data support the
model that Bcl6 function in Treg cells is required for sup-
pression of a Th2 phenotype within Treg cells.21 How-
ever, unlike in Bcl6/ mice, Treg cells from Bcl6Foxp3/
mice did not express detectable levels of cytokines (data
not shown). To determine if exTreg cells in Bcl6Foxp3/
mice had skewing towards the Th2 lineage, as we
observed with Bcl6/ mice, we sorted exTreg cells from
control and Bcl6Foxp3/ FCRR mice induced to develop
allergic airway disease. As shown in Fig. 8(c), exTreg cells
from Bcl6Foxp3/ FCRR mice showed no signs of abnor-
mal Th2 skewing. Bcl6-deficient Treg cells did express sig-
nificantly higher IL-10 mRNA, consistent with IL-10
being a direct target of Bcl6-mediated repression. Overall,
these data show that Bcl6 expression in Treg cells is
required to maintain normal Th2 responses, but that the
extremely strong Th2 responses in Treg and exTreg cells
in Bcl6/ mice is due to the abnormal inflammatory
background.
Lastly, we analysed the level of airway inflammation in
control and Bcl6Foxp3/ mice induced in the allergic air-
way disease model. As shown in Fig. 9(a), strong airway
inflammation was induced in this model. However, there
was no significant increase in the severity of lung inflam-
mation in Bcl6Foxp3/ mice (Fig. 9b) and the overall cell
infiltrate into bronchoalveolar spaces as tested by BAL,
was not significantly different (data not shown). However,
when the BAL cells were analysed more carefully for spe-
cific types of immune cells, although most cell types were
at similar levels between control and Bcl6Foxp3/ mice,
we observed a significant increase in the numbers of T
cells in BAL from Bcl6Foxp3/ mice (Fig. 9c). Hence,
Bcl6-deficient Treg cells are defective in controlling num-
bers of T cells in the lung during Th2 inflammation.
Overall, these data show that specific loss of Bcl6 in Treg
cells has specific and significant influences on the inflam-
matory response in a Th2 model of airway inflammation.
Discussion
We show that the severe Th2-type inflammation in
Bcl6/ mice not only promotes the formation of con-
ventional Th2 responses, but also leads to the formation
of increased numbers of Th2 cytokine-secreting exTreg
cells. We also show for the first time that Bcl6/ Treg
cells can secrete Tconv-like levels of Th2 cytokines; these
data help to explain the inability of Bcl6/ Treg cells to
control Th2-type inflammation.21 These data are novel in
that they show that exTreg cells that formerly expressed
Foxp3 can also become Th2-like, and not only develop
Th1 and Th17 effector capacity, as has been previously
shown.7 We further compare exTreg generation in wild-
type and mutant mice, and observe that enhanced forma-
tion of exTreg cells and increased formation of Th2 cyto-
kine-producing exTreg cells occurs only in the
inflammatory Bcl6/ background. Hence, while signifi-
cant numbers of exTreg cells may be generated in the
wild-type steady-state environment, exTreg cells only pro-
duce high levels of effector cytokines in the inflammatory
environment.
A previous study showed that human Treg cells that
lose Foxp3 after in vitro activation, preferentially develop
into Th2 cytokine-producing cells.26 Another set of stud-
ies using a mouse Treg model showed that attenuated
Foxp3 expression caused Treg cells to preferentially differ-
entiate into Th2 cytokine-producing cells.27,28 Curiously,
conversion of Treg cells into Th2 cytokine-producing cells
was not seen if Foxp3 expression was completely lost.27
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The ubiquitin ligase Itch has been shown to control Th2
responses, and mice with Itch deleted specifically in Treg
cells develop Th2 cytokine-expressing Treg and exTreg
cells similar to what we observe with Bcl6-deficient
mice.29 However, in contrast to our findings, the Th2
pathway controlled by Itch is purely Treg-intrinsic, and
further exTreg cells are not generated at increased pro-
portions.29 Our current data indicate that the Th2-type
inflammation observed in Bcl6/ mice can strongly acti-
vate Th2 cytokine expression in both Treg and exTreg
cells, by a Treg-extrinsic pathway. This Treg-extrinsic
pathway may be relevant to human disease and can help
explain why Treg cells cannot control the Th2 inflamma-
tion that occurs in allergic disease.
The stability of Treg cells has been a controversial topic
in the past, but the recent consensus is that the large
majority of Treg cells, particularly thymus-derived Treg
cells, are very stable and maintain suppressor activity for
their lifetime.13,15 If a small fraction of Treg cells loses
Foxp3 expression, these cells can expand rapidly in vivo,
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Figure 8. T-cell responses in regulatory T (Treg) cell-specific conditional Bcl6/ mice after induction of allergic airway disease. Data from the
spleens of Treg-specific conditional Bcl6/ (Bcl6Foxp3/) (conditional knockout; cKO) mice and control Bcl6+/+ (Bcl6Foxp3+/+) mice, mated to a
Foxp3-GFP-Cre-Rosa26-RFP (FCRR) background and induced to develop allergic airway inflammation by priming with ovalbumin (OVA) -Alum
and repeated nasal OVA challenge. (a, b) Spleen cells were stimulated with PMA plus ionomycin along with Golgi-plug for 6 hr, stained for
CD4, Foxp3, Gata3, interleukin-4 (IL-4) and interferon-c (IFN-c), then analysed by flow cytometry. (c) Since cell fixation destroys the GFP sig-
nal, and precludes exTreg cell analysis by ICS, live GFP– RFP+ exTreg cells were obtained by sorting, then stimulated for 16 hr with anti-CD3
and anti-CD28 antibodies before harvest for RNA isolation. Gene expression was assessed by quantitative PCR. n = 4 to n = 7. NS, not signifi-
cant (P > 005), *P < 005, **P < 001, ****P < 0001.
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due to loss of Foxp3-mediated inhibition of proliferation.
Indeed, the overall percentage of stable Treg cells is not
decreased in Bcl6/ mice, indicating that exTreg cells
may be formed from relatively few Treg cells. Further-
more, the bias towards self-reactivity of Treg cells can
augment the responses of exTreg cells.16 The predominant
question is whether exTreg cells, as observed here, and in
other studies,7,14 represent the loss of Foxp3 by bona fide
Treg cells or whether they represent Tconv cells that tran-
siently induced endogenous Foxp3 and so induced
Foxp3-Cre recombinase, leading to activation of the
lineage tracer (e.g. YFP) expression.14 Once these cells
lose the transient Foxp3 expression, they would be indis-
tinguishable from true exTreg cells. The exTreg popula-
tion we observe in Bcl6/ mice may be a mixture of
both true exTreg and Tconv cells that transiently induced
Foxp3 and then lost expression. The strong Th2-type
inflammation in Bcl6/ mice, plus the loss of Bcl6 in
Treg cells, may lead to Treg instability and increased pro-
duction of true exTreg cells. It is also possible that in
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Figure 9. Inflammatory responses in regulatory T (Treg) cell-specific conditional Bcl6/ mice after induction of allergic airway disease. Treg-
specific conditional Bcl6/ (Bcl6Foxp3/) (conditional knockout; cKO) mice and control Bcl6+/+ (Bcl6Foxp3+/+) mice were induced to develop
allergic airway inflammation. Mice were primed with ovalbumin (OVA) antigen in Alum adjuvant intraperitoneally, and then challenged with
OVA intranasally for 5 consecutive days, as described.21 (a) Representative lung histology on haematoxylin & eosin stained sections showing air-
way inflammation after disease induction. Control-Untreated is a control Bcl6+/+ mouse without any disease induction. Control-allergic airway
disease (AAD) and cKO-AAD are control and cKO mice, respectively, induced to develop allergic airway disease. Strong infiltrates of inflamma-
tory cells are observed around the airways of the AAD mice (b) Lung inflammation scores for Control-AAD and cKO-AAD mice, where the
severity of the inflammatory infiltrate was analysed as described in Materials and methods. Each point shows one mouse. (c) Quantification of
brochoalveolar lavage (BAL) cells obtained from Control-AAD and cKO-AAD mice. BAL cells were counted and assessed for specific cell types by
flow cytometry. Graph shows average number of specific BAL cell types in Control-AAD and cKO-AAD mice. Neut, neutrophils; Eos, eosinophils;
Mac, macrophage; DC, dendritic cells. n = 6 or n = 7. The experiment was performed twice with similar results obtained each time. NS, not
significant (P > 005), *P < 005.
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Bcl6/mice, a very high fraction of conventional T cells
transiently induce Foxp3 (and hence turn on marker
expression), and then lose Foxp3 expression over time,
while also differentiating into Th2-secreting cells. How-
ever, an argument against this possibility is that
pro-inflammatory cytokines appear to inhibit transient
activation-induced Foxp3 expression,14 and so transient
induction of Foxp3 in Tconv cells should be suppressed
in Bcl6/ mice with ongoing inflammatory disease. Con-
sistent with this, we have observed lower Foxp3 expres-
sion in activated Tconv cells from Bcl6/ mice.21
Another argument in favour of GFP YFP+ T cells from
Bcl6/ mice being true exTreg cells is that they have a
slightly different gene expression pattern from conven-
tional CD4 T cells, in that they express markedly less
IFN-c and more Gata3 compared with total Tconv cells
(Fig. 4). However, this difference may be somewhat illu-
sory if the exTreg cells are derived preferentially from
effector Th2 cells generated in Bcl6/ mice. Hence, ex-
Treg cells may produce very similar levels of Th2 cyto-
kines as Tconv cells that are predominantly Th2
differentiated.
Strikingly, the exTreg cells from both Bcl6+/+ and
Bcl6/ mice do not up-regulate IFN-c compared with
Treg levels, in contrast to the exTreg data from Zhou
et al.7 This difference may be due to the NOD mouse
background used in the Zhou et al. study, and the devel-
opment of Th1-type autoimmune inflammation in the
NOD mouse model. Also, unlike Zhou et al., we did not
observe up-regulation of IL-17 in Bcl6+/+ Treg cells.
Interleukin-17 was expressed at higher levels by Bcl6/
exTreg cells than Bcl6+/+ exTreg cells, but IL-17 was not
higher in Bcl6/ exTreg cells compared with Bcl6/
Treg cells. Hence, the main increase in cytokine expres-
sion from Treg to exTreg cells in the Bcl6/ mice is
restricted to Th2 cytokines.
Our data with Bcl6Foxp3/ mice show that in Bcl6/
mice, the in vivo environment leads to the greatly
enhanced generation of Th2 cytokine-expressing exTreg
cells, and that this in vivo environment in Bcl6/ mice is
unique and cannot be mimicked by induction of allergic
Th2 airway inflammation. We are unable to determine
definitively if there is increased instability of true Treg
cells in Bcl6/ mice, or whether there is a large fraction
of Th2-type Tconv that transiently up-regulate Foxp3 to
induce marker expression, and then lose Foxp3 at a high
rate in the ongoing inflammatory response. Since ‘stable’
Treg cells in Bcl6/ mice express high levels of Th2 cyto-
kines, it is likely that Th2 cytokine-expressing exTreg cells
in these mice are derived from the stable Treg cells and
are therefore true exTreg cells. Also, the fact that exTreg
generation was enhanced in control mice induced to
develop allergic airway disease (Fig. 7b) supports the idea
that true wild-type Treg cells can be destabilized to
develop into exTreg cells in an inflammatory response. As
noted above, transient Foxp3 expression should be sup-
pressed by inflammation in Bcl6/ mice. The inflamma-
tory disease in Bcl6/ mice starts at an early age and is
complex in aetiology. While the large generation of Th2
cytokine-expressing exTreg cells may be due to long-term
exposure of Treg cells to Th2 inflammation, a more inter-
esting possibility is that there are unique inflammatory
factors circulating in Bcl6/ mice, not normally found
in Th2 inflammation, that lead to potent Treg cell insta-
bility. A further complicating factor is the intrinsic func-
tion of Bcl6 in Treg cells, and whether loss of Bcl6 in
Treg cells, together with the severe Th2 inflammation in
Bcl6/ mice, leads to an additive or even synergistic
effect on Treg cell instability.
Lastly, our data definitively show a Treg-intrinsic func-
tion for Bcl6 in controlling Treg responses. Although the
Treg-intrinsic role of Bcl6 on Th2 responses is minor
compared with the Treg-extrinsic effects of the inflam-
mation in Bcl6/ mice, as shown by functional stud-
ies,21 we still find a significant role for Bcl6 in Treg cells
for controlling Gata3 expression, T-cell proliferation and
Th2 responses. Our most unexpected finding is the
increased Treg cell numbers found in spleens of
Bcl6Foxp3/ mice as well as the increased T-cell numbers
in the BAL of the mice with induced allergic airway dis-
ease. These data indicate a specific inability of Bcl6-defi-
cient Treg cells to control T-cell numbers in the face of
Th2 inflammation.
Conclusion
These studies provide convincing evidence of a role of
Bcl6 in controlling Th2 inflammatory responses by both
Treg-intrinsic and Treg-extrinsic pathways.
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